Clinical trial
Study of Doxil in the Treatment of Patients With Refractory Idiopathic…
NCT00107913 · Hematology and Oncology Specialists, Other · Unknown status
Key facts
| NCT number | NCT00107913 |
|---|---|
| Title | Study of Doxil in the Treatment of Patients With Refractory Idiopathic Thrombocytopenic Purpura |
| Official title | Phase II Study of Doxil in the Treatment of Patients With Refractory Idiopathic Thrombocytopenic Purpura |
| Lead sponsor | Hematology and Oncology Specialists, Other |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Autoimmune Thrombocytopenic Purpura |
| Intervention type | Drug |
| Interventions | Doxil |
| Enrollment | 10 |
| Start date | Sep 1, 2001 |
| Completion | Apr 1, 2005 |
| First posted | Apr 12, 2005 |
| Last update posted | Jun 24, 2005 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: